JP2023554081A5 - - Google Patents
Info
- Publication number
- JP2023554081A5 JP2023554081A5 JP2023537034A JP2023537034A JP2023554081A5 JP 2023554081 A5 JP2023554081 A5 JP 2023554081A5 JP 2023537034 A JP2023537034 A JP 2023537034A JP 2023537034 A JP2023537034 A JP 2023537034A JP 2023554081 A5 JP2023554081 A5 JP 2023554081A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- variable region
- chain variable
- nucleotide sequence
- sequence seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011485792.8A CN114634575B (zh) | 2020-12-16 | 2020-12-16 | 一种补体抑制剂的开发和应用 |
| CN202011485792.8 | 2020-12-16 | ||
| PCT/CN2021/138447 WO2022127834A1 (zh) | 2020-12-16 | 2021-12-15 | 一种补体抑制剂的开发和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023554081A JP2023554081A (ja) | 2023-12-26 |
| JP2023554081A5 true JP2023554081A5 (https=) | 2024-04-15 |
Family
ID=81944764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537034A Pending JP2023554081A (ja) | 2020-12-16 | 2021-12-15 | 補体抑制剤の開発及び応用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240067751A1 (https=) |
| EP (1) | EP4265641A1 (https=) |
| JP (1) | JP2023554081A (https=) |
| KR (1) | KR20230118941A (https=) |
| CN (4) | CN120173118B (https=) |
| AU (1) | AU2021398697A1 (https=) |
| CA (1) | CA3202507A1 (https=) |
| IL (1) | IL303794A (https=) |
| WO (1) | WO2022127834A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3221859A1 (en) * | 2021-06-08 | 2022-12-15 | Xiaowu Liu | Anti-masp-2 antibody and use thereof |
| JP2024524440A (ja) * | 2021-06-30 | 2024-07-05 | スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド | 新規抗ｍａｓｐ－２抗体 |
| CN116615544A (zh) * | 2021-12-10 | 2023-08-18 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别masp2的抗体及其应用 |
| EP4643878A2 (en) * | 2022-12-29 | 2025-11-05 | Suzhou Transcenta Therapeutics Co., Ltd. | Pharmaceutical preparation comprising therapeutic antibody and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| ES2631127T3 (es) * | 2004-06-10 | 2017-08-28 | Omeros Corporation | Métodos para tratar afecciones asociadas con la activación del complemento dependiente de MASP-2 |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| AU2011265532B2 (en) * | 2004-06-10 | 2014-04-24 | Omeros Corporation | Methods for treating conditions associated with MASP-2-dependent complement activation |
| DK2488203T3 (en) * | 2009-10-16 | 2017-03-13 | Omeros Corp | METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION |
| BR112013025917A2 (pt) * | 2011-04-08 | 2016-12-20 | Omeros Corp | uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2 |
| HUE049154T2 (hu) | 2011-05-04 | 2020-09-28 | Omeros Corp | Készítmények a MASP-2-függõ komplement-aktiválás gátlására |
| AU2013201779B2 (en) * | 2011-05-04 | 2016-01-07 | Omeros Corporation | Compositions for inhibiting MASP-2 dependent complement activation |
| KR102528260B1 (ko) * | 2016-01-05 | 2023-05-04 | 유니버시티 오브 레스터 | 필요로 하는 대상체에서 섬유증의 억제 방법 |
| CN107586339B (zh) * | 2016-07-06 | 2023-01-20 | 尚华科创投资管理（江苏）有限公司 | 一种BLyS抗体及其制备方法和应用 |
| BR112020025841A2 (pt) * | 2018-06-22 | 2021-03-23 | Omeros Corporation | método para prevenir, reduzir e/ou tratar uma doença, distúrbio ou condição associada à ativação induzida por fibrina do sistema complemento e à ativação associada dos sistemas de coagulação e/ou contato |
| CN112062855B (zh) * | 2020-08-26 | 2024-08-30 | 北京天诺健成医药科技有限公司 | 一种含有衔接器的药物治疗剂的开发和应用 |
-
2020
- 2020-12-16 CN CN202510392209.5A patent/CN120173118B/zh active Active
- 2020-12-16 CN CN202011485792.8A patent/CN114634575B/zh active Active
- 2020-12-16 CN CN202510392268.2A patent/CN120173119B/zh active Active
-
2021
- 2021-12-15 AU AU2021398697A patent/AU2021398697A1/en active Pending
- 2021-12-15 EP EP21905760.1A patent/EP4265641A1/en not_active Withdrawn
- 2021-12-15 CA CA3202507A patent/CA3202507A1/en active Pending
- 2021-12-15 WO PCT/CN2021/138447 patent/WO2022127834A1/zh not_active Ceased
- 2021-12-15 KR KR1020237023581A patent/KR20230118941A/ko not_active Withdrawn
- 2021-12-15 IL IL303794A patent/IL303794A/en unknown
- 2021-12-15 US US18/267,680 patent/US20240067751A1/en active Pending
- 2021-12-15 CN CN202180085328.6A patent/CN116648464A/zh active Pending
- 2021-12-15 JP JP2023537034A patent/JP2023554081A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023554081A5 (https=) | ||
| IL303794A (en) | Development and application of an inhibitory complement | |
| CN106211782B (zh) | 抗体-fynomer缀合物 | |
| JP2023509196A5 (https=) | ||
| JP2020513791A5 (https=) | ||
| JP2019503167A5 (https=) | ||
| US20250304717A1 (en) | Camptothecin derivative and ligand-drug conjugate | |
| JP2018527908A5 (https=) | ||
| JP2006505277A5 (https=) | ||
| JP2019522050A5 (https=) | ||
| JP2021500391A5 (https=) | ||
| JP2020511936A5 (https=) | ||
| JP2011207882A5 (https=) | ||
| JP2011505146A5 (https=) | ||
| JP2016503295A5 (https=) | ||
| JP2012070737A5 (https=) | ||
| AU2010248365A1 (en) | Anti-AXL antibody | |
| JP7721142B2 (ja) | Ｍａｓｐ－２阻害剤および使用方法 | |
| JP2023543493A5 (https=) | ||
| JP2011518857A5 (https=) | ||
| CA3214808A1 (en) | Thienopyrrole compounds | |
| JP2026048732A5 (https=) | ||
| WO2024140845A1 (zh) | 一种多臂聚乙二醇-药物偶联物 | |
| JP2011505371A5 (https=) | ||
| JP2024512260A5 (https=) |